journal article·2023-02-24Open access

Glucose Oxidase-Loaded MnFe2O4 Nanoparticles for Hyperthermia and Cancer Starvation Therapy

Monunith Anithkumar, Arunima Rajan S, Ahmaduddin Khan, Beata Kaczmarek, Marta Michalska-Sionkowska, Krzysztof Łukowicz, Anna Maria Osyczka, Jagriti Gupta, Niroj Kumar Sahu

ACS Applied Nano Materials· Volume 6· Issue 4

Abstract

Nanoparticle-mediated starvation therapy is a promising therapeutic approach for cancer treatment. Here, we report a novel therapeutic nanosystem (GOx@PEG-MnFe 2 O 4 ) composed of glucose oxidase (GOx) loaded in polyethylene glycol (PEG) modified manganese ferrite (MnFe 2 O 4 ) nanoparticles (NPs) for cancer starvation therapy. GOx catalyzes the oxidation of glucose to gluconic acid and hydrogen peroxide (H 2 O 2 ) by consuming oxygen (O 2 ) in an acidic environment. Meanwhile, NPs can catalyze the oxidation of H 2 O 2 to generate O 2, which, in turn, aids in the depletion of glucose and eliminate the hypoxia condition. Phase identification, crystal structure, and size of the NPs confirm the cubic spinel structure with an average crystallite size of 21 nm. NPs exhibit good magnetic susceptibility with a magnetization value of ∼75 emu/g at room temperature. Heating potentiality of the NPs with an obtained specific absorption rate (SAR) of 296 W/g proves the efficacy of NPs to act as a heating agent for cancer hyperthermia, which aid for a synergistic therapy combining magnetic hyperthermia with glucose oxidase-based starvation therapy. Fourier transform infrared spectroscopy and thermogravimetry analysis confirm the successful loading of GOx onto the PEG-MnFe 2 O 4 nanosystem. The nanosystem exhibited ∼82% release of GOx in the cancer cell-mimicking environment in an applied magnetic field which is around 1.8 times higher than that in the normal cell-mimicking environment. In vitro assessment against HeLa and Saos-2 cancer cell lines demonstrated anticancer activity and exhibited reduced hemolysis rates. Furthermore, the in vitro results suggested that the NPs are biocompatible and have potential hyperthermic ability. The designed nanosystem is capable of effectuating the tumoricidal effect via cancer starvation therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Centre for Nanotechnology Research, Vellore Institute of Technology, Vellore 632014, India

Nanomaterial and System Laboratory, Major of Mechatronics Engineering, Faculty of Applied Energy System, Jeju National University, Jeju 63243, South Korea

School of Advanced Sciences, Vellore Institute of Technology, Vellore 632014, India

Department of Biomaterials and Cosmetics Chemistry, Faculty of Chemistry, Nicolaus Copernicus University in Torun, Torun 87-100, Poland

Department of Environmental Microbiology and Biotechnology, Faculty of Biology and Veterinary Sciences, Nicolaus Copernicus University in Torun, Torun 87-100, Poland

Department of Cell Biology and Imaging, Institute of Zoology and Biomedical Research, Faculty of Biology, Jagiellonian University, Krakow 30-387, Poland

Chemistry Division, Bhabha Atomic Research Centre Bombay, Mumbai 400085, India

Funding

Science and Engineering Research Board · VIT University

References (58)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.7150/thno.3826110.7150/thno.38261 ↗
3. 10.1016/j.jons.2017.06.00210.1016/j.jons.2017.06.002 ↗
4. 10.1084/jem.2012016210.1084/jem.20120162 ↗
5. 10.1021/acs.nanolett.7b0353110.1021/acs.nanolett.7b03531 ↗
6. 10.1016/S0140-6736(06)68228-710.1016/S0140-6736(06)68228-7 ↗
7. 10.1039/D0BM00408A10.1039/D0BM00408A ↗
8. 10.1039/D0NR05097K10.1039/D0NR05097K ↗
9. 10.1021/acsami.0c1521110.1021/acsami.0c15211 ↗
10. 10.1021/acsami.8b0181810.1021/acsami.8b01818 ↗
11. 10.1021/acsami.7b0681410.1021/acsami.7b06814 ↗
12. 10.1021/acsnano.7b0253310.1021/acsnano.7b02533 ↗
13. 10.1002/ange.20161068210.1002/ange.201610682 ↗
14. 10.1039/C8TB03198C10.1039/C8TB03198C ↗
15. 10.1021/acsomega.0c0538210.1021/acsomega.0c05382 ↗
16. 10.1016/j.ceramint.2020.07.02910.1016/j.ceramint.2020.07.029 ↗
17. 10.1088/2053-1591/ab955e10.1088/2053-1591/ab955e ↗
18. 10.3390/ma307405110.3390/ma3074051 ↗
19. 10.1080/01932691.2019.165663910.1080/01932691.2019.1656639 ↗
20. 10.1039/D0TB02631J10.1039/D0TB02631J ↗
21. 10.1021/acsnano.8b0504210.1021/acsnano.8b05042 ↗
22. 10.1016/j.actbio.2007.05.01110.1016/j.actbio.2007.05.011 ↗
23. 10.1080/21691401.2017.134592010.1080/21691401.2017.1345920 ↗
24. 10.1016/j.enzmictec.2013.01.00410.1016/j.enzmictec.2013.01.004 ↗
25. 10.1063/1.491746310.1063/1.4917463 ↗
26. 10.1021/nl080616310.1021/nl0806163 ↗
27. 10.1021/jp048748h10.1021/jp048748h ↗
28. 10.1002/adma.20070197510.1002/adma.200701975 ↗
29. Clogston, J. D.; Patri, A. K. Zeta Potential Measurement. In Characterization of Nanoparticles Intended for Drug Delivery; McNeil, S. E., Ed. Humana Press: Totowa, NJ, 2011; pp 63–70.10.1007/978-1-60327-198-1_6 ↗
30. 10.1111/cpr.1248810.1111/cpr.12488 ↗
31. 10.1039/C6RA28633J10.1039/C6RA28633J ↗
32. 10.1016/j.colsurfa.2020.12521010.1016/j.colsurfa.2020.125210 ↗
33. 10.3390/nano1011229710.3390/nano10112297 ↗
34. 10.1016/S1040-8428(01)00179-210.1016/S1040-8428(01)00179-2 ↗
35. 10.1039/c3tb20429d10.1039/c3tb20429d ↗
36. 10.1021/acsanm.1c0027410.1021/acsanm.1c00274 ↗
37. 10.1016/j.mtcomm.2021.10258310.1016/j.mtcomm.2021.102583 ↗
38. 10.1016/j.colsurfa.2019.12436410.1016/j.colsurfa.2019.124364 ↗
39. 10.1021/acs.jpcc.6b0142610.1021/acs.jpcc.6b01426 ↗
40. 10.1039/C9TB00569B10.1039/C9TB00569B ↗
41. 10.1039/C4DT03470H10.1039/C4DT03470H ↗
42. 10.1016/j.matchemphys.2012.12.04410.1016/j.matchemphys.2012.12.044 ↗
43. 10.1039/D0RA08699A10.1039/D0RA08699A ↗
44. 10.1039/C4RA15888A10.1039/C4RA15888A ↗
45. 10.1038/s41598-020-71703-610.1038/s41598-020-71703-6 ↗
46. 10.1021/jp507566u10.1021/jp507566u ↗
47. 10.1074/jbc.M20871120010.1074/jbc.M208711200 ↗
48. 10.1002/bit.26015050910.1002/bit.260150509 ↗
49. 10.2116/analsci.27.97910.2116/analsci.27.979 ↗
50. 10.1093/annonc/mdf28010.1093/annonc/mdf280 ↗
51. 10.1039/C9NR04858H10.1039/C9NR04858H ↗
52. 10.3390/antiox903019110.3390/antiox9030191 ↗
53. 10.1002/adfm.20190141710.1002/adfm.201901417 ↗
54. 10.1016/j.msec.2018.08.00510.1016/j.msec.2018.08.005 ↗
55. 10.1039/D1NJ03968G10.1039/D1NJ03968G ↗
56. Kong G. · Cancer Res. · 2000 · 60 · 6950
57. 10.1016/j.msec.2020.11069510.1016/j.msec.2020.110695 ↗
58. 10.1016/j.actbio.2014.04.01110.1016/j.actbio.2014.04.011 ↗